MedTrace Logo

Clinical Association Between Obstructive Sleep Apnea, Facial Pigmentation, and Vasovagal Symptoms.

NCT06331819 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-09-19

No results posted yet for this study

Summary

The goal of this prospective cohort study is to study patients referred for sleep study by in-lab polysomnography in the Jordan University Hospital and the Jordan Hospital or with an at-home sleep study kit. The main aims are:

* To prospectively obtain demographic and clinical information of patients referred for a sleep study.
* To determine the diagnostic value of facial discoloration as potential marker for obstructive sleep apnea to increase detection rate for the condition.
* To establish a correlation between obstructive sleep apnea and vasovagal symptoms with resulting increased smoking tendency and study the effect of treatment on the disorders.
* To determine the association between timing of appearance of obstructive sleep apnea symptoms and initiation of smoking.

Conditions

Interventions

DIAGNOSTIC_TEST

In-lab polysomnography

Patient's brainwaves are recorded overnight to diagnose sleep disorder.

DEVICE

Continuous positive airway pressure

A machine that uses air pressure to keep breathing airways open while patients sleep.

DIAGNOSTIC_TEST

Home sleep study device

Patient's brainwaves are recorded overnight to diagnose sleep disorder.

Sponsors & Collaborators

  • Jordan Collaborating Cardiology Group

    lead OTHER

Principal Investigators

  • Rand M Zaqqa · Jordan University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-10
Primary Completion
2026-01-01
Completion
2026-03-01

Countries

  • Jordan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06331819 on ClinicalTrials.gov